Institution identification

PURI

https://redirect.ema.europa.eu/resource/49626

Institution ID

49626

Institution full name and acronym

Department of Medical Informatics - Health Data Science, Erasmus Medical Center (ErasmusMC)

Institution countries

Netherlands

Type of institution

Educational Institution

Institution role

Data holder

Institution website

ENCePP partner

Yes
Institution description
The Health Data Science group performs methodological research to enable data-driven healthcareThe Health Data Science group performs methodological research using Electronic Health Record data in the area of patient-level prediction and population level-effect estimation. We are highly involved in the Observational Health Data Sciences and Informatics (OHDSI) community that builds analytical pipelines on top of the OMOP Common Data Model (CDM) to generate reliable evidence to improve patient health.For this research we use health care data mapped to the OMOP common data model including the IPCI database which is maintained by our department namely the department of Medical Informatics.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

ADVANCE POC Study Protocol - Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case. Coverage rates of acellular and whole-cell pertussis-containing vaccines in preschool children (ADVANCE Coverage POC)
Arrhythmogenic Potential of Drugs (ARITMO) project
ASSOCIATION BETWEEN THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME (TTS) OR THROMBOEMBOLIC EVENTS, AND COVID-19 VACCINES
DARWIN EU® - Background rates of serious adverse events to contextualise safety assessments in clinical trials and non-interventional studies in adolescent and adult patients with severe asthma
DARWIN EU® - Chondrosarcoma: patient demographics, treatments, and survival in the period 2010-2023
DARWIN EU® - Drug utilisation study on medicinal use of Pelargonii radix
DARWIN EU® Drug utilisation of valproate-containing medicinal products in women of childbearing potential
DARWIN EU® Drug utilization study of prescription opioids
DARWIN EU® DUS of Antibiotics in the ‘Watch’ category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use
DARWIN EU® Overall survival in patients with locally advanced or metastatic non-small cell lung cancer treated with selected immunotherapies as first line of treatment
DARWIN EU® Prevalence of rare blood cancers in Europe
DARWIN EU® – Frailty and polypharmacy among adults with selected cancers at the time of diagnosis
EMIF Use Case 17 - Investigating the relationship in paediatric population between dosing of antibiotics (prescribed, dispensed or administered) and patient’s weight. (EMIF UC17)
EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU ADR ALLIANCE
EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO ADHERENCE TO THE RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE
European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance
European Program of Post-Authorization Safety Studies for Protelos®/Osseor® through EU-ADR Alliance
Evaluation of vaccination error cases with fatal outcome reported to EudraVigilance
Monitoring the effectiveness of risk minimisation in patients treated with pioglitazone-containing products
Multinational, multi-database cohort study to assess adverse cardiovascular and cerebrovascular outcomes and mortality in association with inhaled NVA237 in Europe (NVA237 PASS)
Multinational, multi-database drug utilization study of indacaterol/glycopyrronium bromide in Europe
Multinational, multi-database drug utilization study of inhaled NVA237 in Europe (NVA237 DUS)
Natural history of coagulopathy and use of anti-thrombotic agents in COVID-19 patients and persons vaccinated against SARS-CoV-2
Project Sc(y)lla: SARS-Cov-2 Large-scale Longitudinal Analyses on the comparative safety and effectiveness of treatments under evaluation for COVID-19 across an international observational data network
Ranitidine and other histamine H2-receptor antagonists – a drug utilisation study
Safety Evaluation of Adverse Reactions in Diabetes - Comparative studies (SAFEGUARD)
Safety Evaluation of Adverse Reactions in Diabetes - Drug utilisation studies (SAFEGUARD)
Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of pertussis and pertussis related outcomes of whole-cell pertussis and acellular pertussis vaccines in pre-school children (benefit study on pertussis vaccination)
The European Drug-induced Agranulocytosis Consortium Study (The EuDAC Study)
Utilization of antidementia treatments: a large multinational-network population-based study.
VALIDATION STUDY PROTOCOL (OP0007) FOR THE EUROPEAN NON-INTERVENTIONAL POST- AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS CARDIOVASCULAR EVENTS OF MYOCARDIAL INFARCTION AND STROKE AND ALL-CAUSE MORTALITY FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0004) AND EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0006)